

The Intersection Between Hatch Waxman, PTAB, ITC & ED Texas. Using All The Tools in the Tool Box.

Moderator: Stephanie Barnes (Siebman, Burg, Phillips & Smith)

Panelists: Judge John D. Love (E.D. Tex.)

Jennifer Doan (Haltom & Doan)

Kat Li (McKool Smith)

Thomas Meloro (Willkie Farr & Gallagher LLP)



Hatch Waxman Overview

- > Initiation of Hatch Waxman Litigation
 - Orange Book
 - Generic drug company files ANDA with FDA
 - Brand drug company receives notice and may bring litigation within 45 days
- Unique Statutory Provisions Distinguish Hatch Waxman Litigation from other Patent Litigation
 - ANDA filing is an artificial act of infringement
 - 30-month stay of FDA approval
 - 180-day generic drug exclusivity



ED Texas Local Hatch Waxman Rule

- > Brief history of Local Patent Rule 3-8
- > Provisions of Local Patent Rule 3-8
 - Production of ANDA
 - Invalidity contentions followed by infringement contentions
 - Notification requirements regarding FDA correspondence
 - Final pretrial hearing set 24 months from date of filing
- ED Texas local rule reflects experience adjudicating Hatch Waxman litigation and importance of timing



Unique Hatch Waxman Litigation Issues

- > Bench trial
- No willful infringement
- > Joinder permitted for multiple ANDA filers
 - Exception to AIA
- > New patents issued during litigation
- New evidence by ANDA filer in response to FDA comments
- > Potential "at-risk launch" of generic product



PTAB Proceedings and Hatch Waxman Litigation

- IPR proceedings are increasingly popular tool for challenging pharmaceutical patents
- > Interests of first ANDA filer vs. subsequent ANDA filers
- > Effect of PTAB decision
- > Stay of litigation due to IPR proceeding
 - Alcon Laboratories v. Akorn, 2016 WL 99201 (D.N.J. Jan. 8, 2016)
 - Eli Lilly & Co. v. Accord, 2015 WL 8675158 (S.D. Ind. Dec. 11, 2015)



ITC Proceedings and Hatch Waxman

- > ITC proceedings not as common
 - ITC action not likely a basis for:
 - > 30-month stay; or
 - Injunction barring FDA from approving ANDA
- > ITC actions are a possibility with:
 - Manufacturing process patents not listed in Orange Book
 - Importation of drug into U.S. for manufacture of final product sold overseas
 - Patents for which no 30-month stay would be available in district court action
- > Potential advantages of ITC action:
 - Exclusion orders applicable to multiple suppliers



The Intersection Between Hatch Waxman, PTAB, ITC & ED Texas.

Using All The Tools in the Tool Box.

Questions?